Latest Information Update: 18 Oct 2006
At a glance
- Originator Angelini Group
- Class Eye disorder therapies
- Mechanism of Action Opioid receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Eye disorders